Dedicated to respiratory diagnostics and monitoring
The Company and its technology

- Company established in 2006 & listed on London’s Aim market in 2014

- The Company’s market leading product *NIOX* uses patented technology to accurately measure *Fractional exhaled Nitric Oxide (FeNO) @ ppb level*

- The role that Nitric Oxide (NO) plays in asthma diagnosis was discovered in the 1990’s and established in international guidelines in 2005.

- *NIOX* is registered and reimbursed in all major markets & available in more than 50 countries

- *NIOX* is the device of choice for both Clinical and Research use.
At the forefront of innovation for 20 years
NIOX®: The market leader

NIOX VERO® is the leading ‘point of care’ device for the accurate measurement of Nitric Oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma.

- Circassia owns significant IP portfolio
- NIOX is registered and reimbursed in all major markets.
- Approaching 40 million tests performed to date.
- A worldwide installed base of more than 10,000 NIOX devices.
- ARTP* small diagnostic manufacturer of the year 2019.

* Association for Respiratory Technology and Physiology
More focus on FeNO testing

- Recent European Respiratory Society symposia focussed entirely on raising the awareness and education of FeNO testing
- 340m people are affected worldwide and 1000 people die from asthma every day.
- 50% of asthma is not diagnosed or misdiagnosed
- Today FeNO testing is conducted in less than 5% of the eligible population
Trusted by our customers

MAYO CLINIC
Cleveland Clinic
Yale NewHaven Health
Mount Sinai
JOHNS HOPKINS MEDICINE

vizient
PREMIER
National Jewish Health

Atalograph®
A Global Leader in Respiratory Diagnostics

ERT

NHS
DGP

CIRCASSIA
Dedicated to respiratory diagnostics and monitoring
2019 Clinical and Research Sales

Sales by Destination

- EMEA
- APac
- Americas

Sales by user market

- Clinical
- Research

Sales by product

- Devices
- Consumables

Sales by channel

- Direct
- Distributor